Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model
Molecular and Cellular Endocrinology · 2024
DOI: 10.1016/j.mce.2023.112138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2024. Verfasst von Núbia Alves Grandini und 11 weiteren Autor:innen. Beteiligte Einrichtung: São Paulo State University (UNESP), Medical School, 18618687, Botucatu, Brazil. Electronic address: nubia.grandini@unesp.br. Hauptthemen laut MEDLINE: Carnosine, Metabolic Diseases, Fatty Liver. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Consumption of diets high in sugar and fat is related to the development of Metabolic dysfunction-associated steatotic liver disease (MASLD). Carnosine (CAR) is a dipeptide with antioxidant and anti-inflammatory action and has been studied for treating diseases. This work aimed to evaluate the effects of CAR on diet-induced MASLD in rats. Male Wistar rats were distributed into 2 groups (17 weeks): normocaloric (Co, n = 12), and hypercaloric diet rich in lipids and simple carbohydrates (MASLD, n = 12). After, the animals were redistributed to begin the treatment with CAR (4 weeks): Co (n = 6), Co + CAR (n = 6), MASLD (n = 6), and MASLD + CAR (n = 6), administered intraperitoneally (250 mg/kg). Evaluations included nutritional, hormonal and metabolic parameters; hepatic steatosis, inflammatory and oxidative markers. MASLD group had a higher adiposity index, systolic blood pressure, glucose, plasma and liver triglycerides and cholesterol, insulin, hepatic steatosis, oxidative markers, and lower PPAR-α (Peroxisome Proliferator-activated receptor α), compared to the Co. CAR attenuated plasma and hepatic triglyceride and cholesterol levels, hepatic steatosis, CD68+ macrophages, and hepatic oxidative markers, in addition to increasing HDL cholesterol levels and PPAR-α, compared to the untreated MASLD group. CAR acts in importants pathophysiological processes of MASLD and may be a therapeutic compound to control the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- São Paulo State University (UNESP), Medical School, 18618687, Botucatu, Brazil. Electronic address: nubia.grandini@unesp.br.
- São Paulo State University (UNESP), Medical School, 18618687, Botucatu, Brazil.
- Integrated Colleges of Bauru (FIB), 17056-100, Brazil.
- Department of Pharmaceutical Sciences, University of Milan, 20133, Milan, Italy.
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Grandini, N. A., Costa, M. R., Gregolin, C. S., Siqueira, J. S., Vieira, T. A., Togneri Ferron, A. J., Francisqueti-Ferron, F. V., Romualdo, G. R., Lúcia Dos Anjos Ferreira, A., Aldini, G., Corrêa, C. R., & Moreto, F. (2024). Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2023.112138
Vancouver
Grandini NA, Costa MR, Gregolin CS, Siqueira JS, Vieira TA, Togneri Ferron AJ, et al. Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model. Molecular and Cellular Endocrinology. 2024. doi:10.1016/j.mce.2023.112138
BibTeX
@article{Grandini2024,
author = {Grandini, Núbia Alves and Costa, Mariane Róvero and Gregolin, Cristina Schmitt and Siqueira, Juliana Silva and Vieira, Taynara Aparecida and Togneri Ferron, Artur Junio and Francisqueti-Ferron, Fabiane Valentini and Romualdo, Guilherme Ribeiro and Lúcia Dos Anjos Ferreira, Ana and Aldini, Giancarlo and Corrêa, Camila Renata and Moreto, Fernando},
title = {Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model},
journal = {Molecular and Cellular Endocrinology},
year = {2024},
doi = {10.1016/j.mce.2023.112138}
}
EUVIMED